yes-associated protein

Verteporfin (BPD-MA) is a YAP inhibitor that inhibits YAP-TEAD interactions. Verteporfin is also a photosensitizer used in photodynamic therapy. Verteporfin also induces apoptosis and inhibits autophagy.

AICAR (Acadesine) is an AMPK activator. AICAR has the functions of metabolic regulation, muscle function regulation, anti-cancer effect, neuroprotection and anti-aging.

MYF-01-37 (1-[3-Methyl-3-[3-(trifluoromethyl)anilino]pyrrolidin-1-yl]prop-2-en-1-one) is a novel covalent TEAD inhibitor.

ML-7 hydrochloride (ML-7 HCl) is a cell-permeable, reversible, effective, ATP-competitive, and specific inhibitor of myosin light chain kinase (Ki: 300 nM); also inhibits smooth-muscle myosin light chain kinase, PKA, and PKC.

TED-347 is an irreversible and covalent inhibitor of TEAD4-Yap1 protein-protein interaction(EC50 of 5.9 μM), and inhibits glioblastoma cell viability.

K-975 is a highly selective, orally active TEAD inhibitor, effectively inhibiting protein-protein interactions between TEAD and YAP1/TAZ.

Lats-IN-1 is a potent and ATP-competitive Lats1 and Lats2 kinases inhibitor. It promotes Yap-dependent proliferation in postmitotic mammalian tissues.

mCMY020 is a covalent TEAD inhibitor that effectively reduces YAP (Yes-associated protein)-driven transcription and selectively slows the proliferation of Hippo pathway-deficient cancer cells. It is applicable in cancer research.

PROTACTEAD degrader-1 (Compound 27) is a PROTAC degrader of the transcriptional enhanced associate domain (TEAD). It selectively degrades Flag TEAD2 through a ubiquitin-protease-dependent mechanism, with a DC50 of 54.1 nM in 293T cells. This compound inhibits the proliferation of NF2-deficient NCI-H226 cells, showing an IC50 of 0.21 μM, and modulates the expression of yes-associated protein (YAP) target genes.

TT-10 (TAZ-K), an activator of YES-associated protein (YAP)-transcriptional enhancer factor domain (TEAD) activity, has potential application in heart disease research, specifically for conditions characterized by loss of cardiomyocytes.

TAT-PDHPS1 is a peptide inhibitor targeting Yes-associated protein (YAP) signaling, composed of the endogenous peptide PDHPS1 and the cell-penetrating peptide sequence TAT. It operates by binding to protein phosphatase 2 phosphatase activator (PTPA), thereby activating protein phosphatase 2A (PP2A). This activation precipitates the phosphorylation of YAP, culminating in the suppression of genes targeted by YAP. Demonstrated to inhibit the proliferation of ovarian cancer cells in vitro and reduce ovarian tumor growth in a subcutaneous xenograft mouse model, TAT-PDHPS1 presents a potent approach to managing ovarian malignancies.